It is expected that more future studies will explore the impact of structural and functional differences among specific TP53 mutations on patient outcomes, which might potentially make TP53 comutated EGFR‐mutant NSCLC more actionable and targetable in a better precision‐based era. The gene discussed is TP53; the disease is non-small cell lung carcinoma.